Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MedCAC To Ponder Cost Question At Virtual Colonoscopy Meeting

This article was originally published in The Gray Sheet

Executive Summary

CMS wants an advisory board to consider the costs per life years saved for computed tomography colonography at a Nov. 19 meeting

You may also be interested in...



Cost-Effectiveness Policy In Brief

CMS coverage chief calls for cost consideration: The Medicare agency does not consider the cost of an item during the coverage process, but "we should," says Steve Phurrough, director of the coverage and analysis group in the CMS Office of Clinical Standards and Quality. Speaking Dec. 3 at a conference on value-based purchasing led by the ECRI Institute, Phurrough says that the high cost of a device might lead the coverage team to consider the technology for a potential national coverage determination, but CMS does not evaluate cost in the national coverage process. The policy may change in the future, but the agency will wait to "see what happens in the months ahead, as Congress and the new administration give us whatever guidance they're going to give us." Phurrough and other leaders from government, industry, medicine and academia met for the two-day conference in Washington, D.C., to address the role of comparative effectiveness, cost effectiveness and pay-for-performance in health reform. Recently, CMS asked its Medicare Evidence Development and Coverage Advisory Committee to consider cost as part of a national coverage determination process for computed tomography colonoscopy (1"The Gray Sheet" Nov. 3, 2008, p. 10)

Cost-Effectiveness Policy In Brief

CMS coverage chief calls for cost consideration: The Medicare agency does not consider the cost of an item during the coverage process, but "we should," says Steve Phurrough, director of the coverage and analysis group in the CMS Office of Clinical Standards and Quality. Speaking Dec. 3 at a conference on value-based purchasing led by the ECRI Institute, Phurrough says that the high cost of a device might lead the coverage team to consider the technology for a potential national coverage determination, but CMS does not evaluate cost in the national coverage process. The policy may change in the future, but the agency will wait to "see what happens in the months ahead, as Congress and the new administration give us whatever guidance they're going to give us." Phurrough and other leaders from government, industry, medicine and academia met for the two-day conference in Washington, D.C., to address the role of comparative effectiveness, cost effectiveness and pay-for-performance in health reform. Recently, CMS asked its Medicare Evidence Development and Coverage Advisory Committee to consider cost as part of a national coverage determination process for computed tomography colonoscopy (1"The Gray Sheet" Nov. 3, 2008, p. 10)

House members push for CT Colonography NCD

Six House members, led by Rep. Barbara Cubin, R-Wyo., want CMS to approve a national coverage determination for computed tomography colonography as a screening test for colorectal cancer - a proposal that the agency will be taking up at a Medicare Evidence Development & Coverage Advisory Committee meeting on Nov. 19 ("1The Gray Sheet" Nov. 3, 2008, p. 10). Cubin, along with Reps. Ed Towns, D-N.Y., Chip Pickering, R-Miss., Charlie Wilson, D-Ohio, John Sullivan, R-Okla., and Tammy Baldwin, D-Wis., told CMS in an Oct. 24 letter that allowing CTC, also known as "virtual colonoscopy," to be covered under an NCD would provide a cheaper alternative to traditional optical colonoscopies for patients and would result in more patients getting screened for cancer

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026745

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel